title: Use of monoclonal antibodies for proprotein convertase subtilisin kexin type 9 inhibition: issues with efficacy, tolerability and safety.
authors.affiliation: Department of Diabetes and Endocrinology, University Hospital of Wales, Cardiff, UK.
authors.forename: Gautam
authors.initials: G
authors.lastname: Das
authors.forename: Alan
authors.initials: A
authors.lastname: Rees
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000276:immunology*; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D000960:Hypolipidemic Agents / Q000009:adverse effects* / Q000276:immunology*; D000071449:Proprotein Convertase 9; D043484:Proprotein Convertases / Q000276:immunology*; D012449:Safety; D012697:Serine Endopeptidases / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal; D000960:Hypolipidemic Agents; C472125:PCSK9 protein, human; D000071449:Proprotein Convertase 9; D043484:Proprotein Convertases; D012697:Serine Endopeptidases